血清microRNA生物标志物组合用于高危人群胃癌检测的建立与验证
本研究在新加坡和韩国5248名受试者中分三阶段开发并验证血清12-miRNA组合检测胃癌。前瞻性队列4566例有症状接受内镜检查者中,总体敏感性87.0%(95%CI 79.4%~92.5%),特异性68.4%(95%CI 67.0%~69.8%),AUC 0.848,高于幽门螺杆菌血清学、胃蛋白酶原、ABC法、CEA和CA19-9。作者认为该检测可能对胃癌风险评估具有成本效益。
要点
- 12-miRNA组合在发现队列AUC=0.93,验证队列AUC=0.92。
- 前瞻性队列敏感性87.0%、特异性68.4%,AUC 0.848。
- 每年需筛查人数为489,增量成本效果比为44531美元/质量调整生命年。
核心结论
- 作者建立并验证了血清12-miRNA生物标志物检测,认为其可能对胃癌风险评估具有成本效益。
研究设计与样本
- 三阶段多中心研究,共纳入新加坡和韩国5248名受试者。
- 生物标志物发现与验证阶段通过全面血清miRNA谱分析和多变量分析,在682名受试者的回顾性队列中评估578个miRNA候选物。
- 临床检测在4566名接受内镜检查的有症状受试者的前瞻性队列中开发并验证。
- 检测性能以组织学诊断确认,并与幽门螺杆菌血清学、血清胃蛋白酶原、ABC法、癌胚抗原和癌抗原19-9比较。
- 使用马尔可夫决策模型分析成本效益。
主要发现
- 12-miRNA组合在发现队列的AUC=0.93(95%CI 0.90~0.95),在验证队列的AUC=0.92(95%CI 0.88~0.96)。
- 前瞻性研究中,总体敏感性为87.0%(95%CI 79.4%~92.5%),特异性为68.4%(95%CI 67.0%~69.8%)。
- AUC为0.848(95%CI 0.81~0.88),高于幽门螺杆菌血清学(0.635)、胃蛋白酶原1/2比值(0.641)、胃蛋白酶原指数(0.576)、ABC法(0.647)、癌胚抗原(0.576)和癌抗原19-9(0.595)。
- 每年需筛查人数为489。
- 相对于当前实践,用于大规模筛查具有成本效益(增量成本效果比=44531美元/质量调整生命年)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: An unmet need exists for a non-invasive biomarker assay to aid gastric cancer diagnosis. We aimed to develop a serum microRNA (miRNA) panel for identifying patients with all stages of gastric cancer from a high-risk population. DESIGN: We conducted a three-phase, multicentre study comprising 5248 subjects from Singapore and Korea. Biomarker discovery and verification phases were done through comprehensive serum miRNA profiling and multivariant analysis of 578 miRNA candidates in retrospective cohorts of 682 subjects. A clinical assay was developed and validated in a prospective cohort of 4566 symptomatic subjects who underwent endoscopy. Assay performance was confirmed with histological diagnosis and compared with Helicobacter pylori (HP) serology, serum pepsinogens (PGs), 'ABC' method, carcinoembryonic antigen (CEA) and cancer antigen 19-9 (CA19-9). Cost-effectiveness was analysed using a Markov decision model. RESULTS: We developed a clinical assay for detection of gastric cancer based on a 12-miRNA biomarker panel. The 12-miRNA panel had area under the curve (AUC)=0.93 (95% CI 0.90 to 0.95) and AUC=0.92 (95% CI 0.88 to 0.96) in the discovery and verification cohorts, respectively. In the prospective study, overall sensitivity was 87.0% (95% CI 79.4% to 92.5%) at specificity of 68.4% (95% CI 67.0% to 69.8%). AUC was 0.848 (95% CI 0.81 to 0.88), higher than HP serology (0.635), PG 1/2 ratio (0.641), PG index (0.576), ABC method (0.647), CEA (0.576) and CA19-9 (0.595). The number needed to screen is 489 annually. It is cost-effective for mass screening relative to current practice (incremental cost-effectiveness ratio=US$44 531/quality-of-life year). CONCLUSION: We developed and validated a serum 12-miRNA biomarker assay, which may be a cost-effective risk assessment for gastric cancer. TRIAL REGISTRATION NUMBER: This study is registered with ClinicalTrials.gov (Registration number: NCT04329299).
引用
- So JBY, Kapoor R, Zhu F, et al. Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population. Gut. 2020. PMID: 33028667. doi:10.1136/gutjnl-2020-322065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。